Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc.

December 14, 2007 16:10 ET

Critical Outcome Technologies Inc. Announces Organizational Realignment Following Acquistion of DDP Therapeutics

LONDON, ONTARIO--(Marketwire - Dec. 14, 2007) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced today that the Company is implementing an organizational development and growth plan to address changes resulting from the acquisition of DDP Therapeutics (DDP) and anticipated increases in business activity.

"Over the last 12 months Critical Outcome Technologies Inc. (COTI) has made considerable progress in advancing our product pipeline and developing important industry relationships", said Dr. Wayne Danter, President and CSO of COTI. "Our proprietary technology CHEMSAS® and our novel small molecules have been well-received by prospective partners. In the next 12-18 months we anticipate increased business activity, as we further develop key relationships via profitable collaborations, including our Merck Serono pilot project, additional pilot projects with other pharmaceutical organizations and the potential out-licensing of lead compounds from the small cell lung cancer (SCLC) library recently acquired from DDP. In order to allow us to capitalize on the positive momentum we have built, we will be adding skilled professionals to our science, finance and business development departments in the next 2-3 months."

The Company also announced that Mr. Scott Baker has left COTI to pursue a leadership position within the branded pharmaceutical industry, effective December 14th, 2007. Mr. Baker served as COTI's COO since April 1, 2007 with a focus on supporting DDP on behalf of COTI in the development of the SCLC library and the acquisition of DDP. "On behalf of COTI's Board and the entire management team, I wish to thank Scott for his dedication and efforts in helping bring the Company to this stage of development", said Mr. John Drake, Chairman and CEO of COTI. "Scott's valuable contribution towards the SCLC library development and the DDP acquisition were greatly appreciated. We wish him well in his future endeavours."

COTI has temporarily assigned Mr. Baker's areas of responsibility to its President and CSO, Dr. Wayne Danter, pending the addition of new staff consistent with the implementation of its evolving organizational strategy.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information